References

Anderson, J. L., B. D. Horne, S. M. Stevens, A. S. Grov, S. Barton, Z. P. Nicholas, S. F. Kahn, H. T. May, K. M. Samuelson, J. B. Muhlestein, and J. F. Carlquist. 2007. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anti-coagulation. Circulation 116(22):2563–2570.

Ansell, J., J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti. 2008. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):160S–198S.

Caraco, Y. S., S. Blotnic, and M. Muszkat. 2008. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther 83(3):460–470.

Eckman, M. H., J. Rosand, S. M. Greenberg, and B. F. Gage. 2009. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150(2):73–83.

EGAPP (Evaluation of Genomic Applications in Practice and Prevention) Working Group. 2009. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41.

Flockhart, D. A., D. O’Kane, M. S. Williams, and M. S. Watson. 2008. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10(2):139–150.

Hampel, H., W. L. Frankel, E. Martin, M. Arnold, K. Khanduja, P. Kuebler, M. Clendenning, K. Sotamaa, T. Prior, J. A. Westman, J. Panescu, D. Fix, J. Lockman, J. LaJeunesse, I. Comeras, and A. de la Chapelle. 2008. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788.

Higashi, M. K., D. L. Veenstra, L. M. Kondo, A. K. Wittkowsky, S. L. Srinouanprachanh, F. M. Farin, and A. E. Rettie. 2002. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690–1698.

Hughes, D. A. and M. Pirmohamed. 2007. Warfarin pharmacogenetics: Economic considerations. Pharmacoeconomics 25(11):899–902.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 55
References Anderson, J. L., B. D. Horne, S. M. Stevens, A. S. Grov, S. Barton, Z. P. Nicholas, S. F. Kahn, H. T. May, K. M. Samuelson, J. B. Muhlestein, and J. F. Carlquist. 2007. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anti- coagulation. Circulation 116(22):2563–2570. Ansell, J., J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti. 2008. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evi- dence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):160S–198S. Caraco, Y. S., S. Blotnic, and M. Muszkat. 2008. CYP2C9 genotype-guided warfarin pre- scribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther 83(3):460–470. Eckman, M. H., J. Rosand, S. M. Greenberg, and B. F. Gage. 2009. Cost-effectiveness of us- ing pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150(2):73–83. EGAPP (Evaluation of Genomic Applications in Practice and Prevention) Working Group. 2009. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41. Flockhart, D. A., D. O’Kane, M. S. Williams, and M. S. Watson. 2008. Pharmacogenetic test- ing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10(2):139–150. Hampel, H., W. L. Frankel, E. Martin, M. Arnold, K. Khanduja, P. Kuebler, M. Clendenning, K. Sotamaa, T. Prior, J. A. Westman, J. Panescu, D. Fix, J. Lockman, J. LaJeunesse, I. Comeras, and A. de la Chapelle. 2008. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788. Higashi, M. K., D. L. Veenstra, L. M. Kondo, A. K. Wittkowsky, S. L. Srinouanprachanh, F. M. Farin, and A. E. Rettie. 2002. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690–1698. Hughes, D. A. and M. Pirmohamed. 2007. Warfarin pharmacogenetics: Economic consider- ations. Pharmacoeconomics 25(11):899–902. 

OCR for page 55
 ThE VALuE Of GENETIC AND GENOMIC TEChNOLOGIES IWPC (International Warfarin Pharmacogenetics Consortium). 2009. Estimation of the warfa- rin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753–764. Kangelaris, K. N., S. Bent, R. L. Nussbaum, D. A. Garcia, and J. A. Tice. 2009. Genetic test- ing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 24(5):656–664. Limdi, N. A., G. McGwin, J. A. Goldstein, T. M. Beasley, D. K. Arnett, B. K. Adler, M. F. Baird, and R. T Acton. 2008. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321. Meckley, L. M., J. M. Gudgeon, J. L. Anderson, M. S. Williams, and D. L. Veenstra. 2010. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28(1):61–74. Mvundura, M., S. D. Grosse, H. Hampel, and G. E. Palomaki. 2010. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12(2):93–104. Patrick, A. R., J. Avorn, and N. K. Choudhry. 2009. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2(5):429–436. Rieder M. J., A. P. Reiner, B. F. Gage, D. A. Nickerson, C. S. Eby, H. L. McLeod, D. K. Blough, K. E. Thummel, D. L. Veenstra, and A. E. Rettie. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285–2293. USPSTF (U.S. Preventive Services Task Force). 1996. Guide to Clinical Preventive Services, nd Edition. Available at www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hscps2ed1996 (accessed May 18, 2010). Veenstra, D. L. 2007. The cost-effectiveness of warfarin pharmacogenomics. J Thromb hae- most 5(9):1974–1975.